Table 4 Treatment and follow-up of 126 patients with neuroendocrine carcinoma of the breast in China
From: Neuroendocrine carcinoma of the breast: a review of 126 cases in China
Treatment and follow-up | No. of cases (%) |
|---|---|
Surgery | |
 Mastectomy | 100 (79.4) |
 Breast-conserving surgery | 18 (14.3) |
 Other breast surgery | 7 (5.5) |
 No surgery (chemotherapy alone) | 1 (0.8) |
 Axillary lymph node dissection | 104 (82.5) |
Neoadjuvant therapy | |
 Received | 4 (3.2) |
 None | 122 (96.8) |
Adjuvant therapy | |
 Chemotherapy | 55 (43.7) |
  Infiltrative ductal carcinoma of the breast regimen | 53 (42.1) |
  Small cell carcinoma regimen | 2 (1.6) |
 Radiotherapy | 22 (17.5) |
 Endocrine therapy | 80 (63.5) |
  Tamoxifen | 71 (56.3) |
  Aromatase inhibitors | 4 (3.2) |
  Tamoxifen followed by aromatase inhibitors | 1 (0.8) |
  Regimen not mentioned | 4 (3.2) |
Follow-up | |
 Alive without tumor | 101 (80.2) |
 Alive with tumor | 9 (7.1) |
 Died of disease | 7 (5.6) |
 Died of other causes | 1 (0.8) |
 Lost to follow-up | 8 (6.3) |